ArticleAntibiotics (Basel, Switzerland)2021
Clinical Outcomes and Safety of Meropenem-Colistin versus Meropenem-Tigecycline in Patients with Carbapenem-Resistant
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Comorbidities and mortality in colistin-resistant gram-negative infections among hospitalized patients in Qassim, Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- Effect of Meropenem, Sulbactam, and Colistin Combinations on Resistance Gene Expression in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Extensively drug-resistant Acinetobacter baumannii lung abscess and empyema in a patient with fulminant mycoplasma pneumoniae pneumonia.Respiratory medicine case reports · 2025Article
- Treatment of infections caused by carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Review
- Clinical efficacy and safety of tigecycline based on therapeutic drug monitoring for carbapenem-resistant Gram-negative bacterium pneumonia in intensive care units.BMC infectious diseases · 2023Article
- The clinical features and genomic epidemiology of carbapenem-resistant Acinetobacter baumannii infections at a tertiary hospital in Vietnam.Journal of global antimicrobial resistance · 2023Article
- Clinical effectiveness of tigecycline in combination therapy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective multi-centre observational study.Journal of intensive care · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study compared the clinical outcomes and safety of meropenem-colistin versus meropenem-tigecycline in the treatment of adult patients with carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.